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Background: Recently, metabolic syndrome (MS) has gained attention in human metabolic medicine given its
associations with development of type 2 diabetes mellitus and cardiovascular disease. Canine obesity is associated
with the development of insulin resistance, dyslipidaemia, and mild hypertension, but the authors are not aware
of any existing studies examining the existence or prevalence of MS in obese dogs.
Thirty-five obese dogs were assessed before and after weight loss (median percentage loss 29%, range 10-44%).
The diagnostic criteria of the International Diabetes Federation were modified in order to define canine
obesity-related metabolic dysfunction (ORMD), which included a measure of adiposity (using a 9-point body
condition score [BCS]), systolic blood pressure, fasting plasma cholesterol, plasma triglyceride, and fasting
plasma glucose. By way of comparison, total body fat mass was measured by dual-energy X-ray absorptiometry,
whilst total adiponectin, fasting insulin, and high-sensitivity C-reactive protein (hsCRP) were measured using
validated assays.
Results: Systolic blood pressure (P= 0.008), cholesterol (P= 0.003), triglyceride (P= 0.018), and fasting insulin
(P< 0.001) all decreased after weight loss, whilst plasma total adiponectin increased (P= 0.001). However, hsCRP
did not change with weight loss. Prior to weight loss, 7 dogs were defined as having ORMD, and there was no
difference in total fat mass between these dogs and those who did not meet the criteria for ORMD. However,
plasma adiponectin concentration was less (P= 0.031), and plasma insulin concentration was greater (P= 0.030)
in ORMD dogs.
Conclusions: In this study, approximately 20% of obese dogs suffer from ORMD, and this is characterized by
hypoadiponectinaemia and hyperinsulinaemia. These studies can form the basis of further investigations to
determine path genetic mechanisms and the health significance for dogs, in terms of disease associations
and outcomes of weight loss.
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Recently, metabolic syndrome (MS) has gained attention
in human medicine given its associations with develop-
ment of diabetes mellitus and cardiovascular diseases
[1]. Central obesity (determined by waist circumference)
is critical to its definition, in conjunction with dyslipi-
daemia, hypertension and glucose intolerance. This sug-
gests that MS is a complex cluster of metabolic risk
factors that together may predispose to development of* Correspondence: ajgerman@liv.av.uk
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distribution, and reproduction in any mediumsecondary diseases [1]. In humans, MS doubles the risk
of cardiovascular disease whilst the risk of diabetes mel-
litus is increased five-fold [2]. More recently, proteinuria
(or microalbuminuria) has been observed in patients
with MS, suggesting altered renal function [3-5].
In veterinary medicine, equine MS is well described
[6-8], and known to be a risk factor for laminitis
amongst other pathologies [9,10]. Canine obesity is asso-
ciated with the development of insulin resistance, altered
lipid profiles, and mild hypertension, which are amelio-
rated by weight loss [11-13]. Furthermore, overweight
dogs are more likely to suffer from diabetes mellitus [14],
whilst lifelong overfeeding leads to being overweight,Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Although laboratory dogs, rendered obese by overfeeding,
have many features that resemble human MS [13], the
authors are not aware of any studies examining the exist-
ence of MS in obese dogs. Therefore, the objective of the
present study was to determine whether canine obesity-
related metabolic dysfunction (ORMD, using a definition
modified from that used for human MS) could be identi-
fied in pet dogs with naturally-occurring obesity, and
whether it correlated with specific patient characteristics
(e.g. signalment, body fat content), metabolic (e.g. adipo-
nectin, insulin) and inflammatory (e.g. high-sensitivity C-
reactive protein; hsCRP) biomarkers. We also determined
the effect of weight loss on MS and its consequences.
Methods
Animals
Dogs were referred to the Royal Canin Weight Manage-
ment Clinic, University of Liverpool UK, for inves-
tigation and management of obesity and associated
metabolic disorders. Sixty-five dogs were recruited
between February 2005 and August 2010, and those suc-
cessfully losing weight had completed by January 2011.
Eligibility criteria included confirmation of obesity (e.g.
body fat mass >35%, as measured by dual-energy X-ray
absorptiometry; DEXA; [16]), completing a weight loss
programmed, and having sufficient surplus plasma to
enable analyses to be completed.
Ultimately, a group of 35 dogs fulfilled the inclusion
criteria. The median age was 72mo (12 to 132mo);
twenty dogs were male (19 neutered) and 15 were female
(13 neutered). Nine of the dogs were Labrador retrie-
vers, and a range of other breeds were also represented
including Akita, Border Collie, Cairn Terrier, CKCS (3),
Cocker Spaniel, Corgi, Dachshund, Doberman (2),
English Bull Terrier, Golden Retriever, Irish Setter, Lhasa
Apso, Miniature Schnauzer, Mixed Breed (3), Pug (3),
Samoyed, Schipperke, and Yorkshire Terrier (2). None
of the dogs enrolled participated in a previous study
examining metabolic effects of obesity [12], but many
participated in a separate study examining renal biomar-
kers [17].
The study protocol adhered to the University of Liver-
pool Animal Ethics Guidelines, and was approved by
both the University of Liverpool Research Ethics Com-
mittee and the WALTHAM ethical review committee.
Owners of all participating animals gave informed writ-
ten consent.
Weight loss regimen
Full details of the weight loss regimen have been previ-
ously described [12,18]. Briefly, dogs were determined
to be systemically well, and without significant abnor-
malities on complete blood count, serum biochemicalanalysis and urinalysis. Throughout weight loss, patients
were weighed on electronic weigh scales (Soehnle
Professional), which were regularly calibrated using test
weights (Blake and Boughton Ltd). The degree of
adiposity was estimated, clinically, using a 9-integer body
condition score (BCS) system [19].
The weight management protocol has been previously
described in detail [12,18], and involved using either a
high protein high fiber (Satiety Support, Royal Canin;
34 dogs) or a high protein moderate fiber (Obesity
Management, Royal Canin; 1 dog) weight loss diet
(Table 1). The initial food allocation for weight loss was
determined by first estimating maintenance energy re-
quirement (MER= 440 kJ [105Kcal] × body weight [kg]
0.75/day; [20] using the estimated target weight. The
exact level of restriction for each dog was then indivi-
dualized based upon gender and other factors (i.e. pres-
ence of associated diseases), and was typically between
50-60% of MER at target weight [18]. Owners also
implemented lifestyle and activity alterations to assist in
weight loss. Dogs were reweighed every 7-21 days and
changes made to the dietary plan if necessary, until their
target weight was reached [12,18].
Body composition analysis
Body composition was analyzed before and after the
weight loss regime in all dogs, using fan-beam DEXA
(Lunar Prodigy Advance; GE Lunar). Pre-weight loss
total body composition results were used to estimate tar-
get weight [18,21]. Further, by comparing pre- and post-
weight loss DEXA scan results, change in fat and lean
mass could be estimated [12,18].
Definition of metabolic syndrome
The guidelines of the International Diabetes Federation
[22] were modified in order to produce an accessible
system for dogs. Accordingly, we defined ORMD, using
the either the upper limit of the reference range for
the laboratory used (e.g. cholesterol, triglyceride, and
glucose), or based upon internationally accepted criteria
defining borderline results (e.g. SBP) [23]. Therefore, the
final definition was as follows:
a) BCS 7-9/9
b) AND any two of the following:1. Triglycerides >200 mg/dL, (2.3 mmol/L).
2. Total cholesterol > 300 mg/dL (7.8 mmol/L).
3. Systolic blood pressure >160 mmHg.
4. Fasting plasma glucose >100 mg/dL (5.6 mmol/L),
or previously diagnosed type 2 diabetes mellitus.The prevalence of metabolic syndrome before and
after weight loss was assessed based upon these criteria.
Table 1 Composition of diets used for weight loss
Criterion HPHF diet HPMF diet
ME content* 2900 Kcal/kg 3275 Kcal/kg
Moisture 9.0 9.0
Per 100 g DM g/1000 Kcal (ME) Per 100 g DM g/1000 Kcal (ME)
Moisture 8 28 9 27
Crude protein 30 103 34 104
Crude fat 10 34 10 31
Crude fibre 17.5 60 11.5 35
Total dietary fibre 28 97 18.5 56
Ash 5.3 18 7.9 24
Fibre sources Cellulose, beet pulp, FOS, psyllium husk, diet cereals Cellulose, beet pulp, diet cereals
HPHF=High protein high fibre dietd. HPMF=High protein medium fibree. ME=Metabolisable energy content, as measured by animal trials according to the
American Association of American Feed Control Officials protocols; DM=dry matter; FOS= fructo-oligo-saccharides.
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Blood pressure was measured non-invasively using an oscil-
lometric method (Cordell Veterinary Monitor 9401BP;
Paragon Medical). All dogs were fully conscious, and either
in a sitting position or in dorsal recumbence. A cuff, of
appropriate size (~40% width of the leg) was used, and
placed on the right forelimb. Once the dog was calm and
not moving, at least five readings were taken and averaged
to produce a result for systolic blood pressure (SBP).
Clinical sampling and biochemical parameters
Blood samples were collected by jugular venepuncture
prior to and after the weight loss period. All blood samples
were taken after a fast of at least 16 h. Plasma cholesterol,
triglycerides, and fasting plasma glucose concentrations
were performed in an automated clinical chemistry
analyzer (Olympus AU2700, Olympus Diagnostic GmbH)
with intra and inter-assay CVs <2% for all the analyses.
Plasma adiponectin and insulin concentrations were
determined using ELISA kits (Human Adiponectin
ELISA, High Sensitivity Kit, BioVendor-Labaratorni
Medicine for adiponectin; and Insulin, Canine ELISA,
Mercodia AB, Uppsala, Sweden for insulin). Intra and
inter-assay coefficient of variations (CVs) were < 11%
and< 8% for adiponectin and insulin, respectively [24,25].
High sensitivity CRP (hs-CRP) was measured with a
time-resolved immuno fluorometric assay with intra and
inter-assay CVs of <14% [26].
Assessment of the consequences of ORMD in dogs
In order to assess the significance of ORMD, comparisons
were made between groups of dogs defined as having and
not having metabolic syndrome. The parameters assessed
included, signalment data, starting body weight, pre-
weight loss body fat percentage, pre-weight loss plasma
metabolic biomarkers (e.g. insulin, CRP, and adiponectin),
rate of weight loss, energy intake required for weight loss,
and change in lean tissue mass during weight loss.Statistical analysis
Data are expressed as median (range) except where indi-
cated. Statistical analyses were performed with computer
software (Stats Direct version 2.6.8; Stats Direct Ltd.),
with the level of significance set at P < 0.05 for two-sided
analyses. The Shapiro-Walk test was first used to assess
whether or not data were normally distributed and,
given that the majority of datasets were not normally
distributed, non-parametric tests were chosen for all
analyses. Differences in the concentrations of the various
biomarkers, prior to and after weight loss, were assessed
with the Wilcoxon signed rank sums test, whilst differ-
ences in the number of dogs affected by ORMD pre-
and post-weight loss were compared with an exact test
for matched pairs [27]. Comparisons between groups of
dogs with and without ORMD were made with the
Mann–Whitney test. Finally, a possible association be-
tween pre-weight loss adiponectin and insulin concen-
trations was tested with Kendall’s rank correlation.
Results
Baseline characteristics and outcomes of weight loss
Median body weight prior to weight loss was 32.9 kg
(5.4 to 77.0 kg), and decreased to 25.6 kg (4.4 to 51.4 kg)
after weight loss. Median BCS decreased from 8 (7-9)
prior to weight loss to 5 (4 to 6) after weight loss.
Weight loss took a median of 259 days (91 to 674 days),
and a median weekly rate of 0.8%/week (0.2 to 1.4%). As
a result, median percentage weight loss was 29% (9% to
44%). The choice of weight loss diet had no effect on the
results obtained (data not shown).
Changes in body composition and plasma metabolic
biomarkers with weight loss
Median total body fat percentage decreased significantly
upon weight loss (median change -53%, range -16 to
-78%, P < 0.001). Although some dogs gained lean tissue
mass during the process, most lost lean tissue, and the
Table 3 The number of animals with BCS, SBP,
cholesterol, triglyceride, and glucose above the upper
reference limit pre- and post-weight-loss




Body condition score2 >6/9 35 0
Cholesterol >7.8 mmol/L 4 0
Triglycerides >0.23 mmol/L 3 0
SBP3 >160 mmHg 10 8
Glucose >5.5 mmol/L 11 8
1 Upper limit: the upper reference range limit used for the definition of
metabolic syndrome. 2 Body condition score assessed with a 9-integer scale
[19]. 3 Systolic blood pressure, measured indirectly by an oscillometric
technique. All results are expressed as mean, median (range) & number above
upper limit; the exception is except for body condition score (BCS), where the
mean values are not reported as the data were categorical.
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to 9%, P < 0.001).
BCS (P < 0.001), SBP (P= 0.008), plasma cholesterol
concentration (P= 0.003), plasma triglyceride concentra-
tion (P= 0.018), plasma insulin concentration (P < 0.001),
and UPCR (P= 0.034) all decreased after weight loss
(Table 2), whilst plasma adiponectin concentration
increased (P= 0.001). Plasma hs-CRP (P= 0.822) and
plasma glucose (P= 0.166) concentrations did not
change with weight loss.
Identification of dogs with ORMD
When different ORMD criteria were studied individu-
ally, all dogs had a BCS 7-9/9 prior to weight loss,
whereas the BCS range after weight loss was 4-6/9
(Table 3). Although, after weight loss, the BCS of 6 dogs
was 6/9 (i.e. above the optimal range for healthy dogs
of BCS 4-5/9, [15], there was no association with per-
sistence of abnormal metabolic parameters (data not
shown). Prior to weight loss, occasional results, above
respective upper reference limits, were noted for choles-
terol (4/35) and triglycerides (3/35), but these were no
longer evident after weight loss. In contrast, increases in
SBP (10/35) and plasma glucose (11/35) were more
common prior to weight loss, and many remained above
the upper limit after weight loss (SBP 8/35 and glucose
7/35) (Table 3). When BCS and 4 parameters (i.e. trigly-
cerides, cholesterol, SBP, and glucose) were used in the
definition of ORMD, 7/35 fulfilled the criteria before
weight loss (Table 3).
Comparison of obese dogs with and without ORMD
pre-weight loss
To determine factors associated with ORMD baseline
data, pre-weight loss body composition analysis results,Table 2 Pre- and post-weight-loss metabolic biomarkers






BCS1 8 (7-9) 5 (4-6) <0.001
SBP2 (mmHg) 155 (108-220) 130 (105-180) 0.008
Cholesterol (mmol/L) 5.6 (2.5-9.3) 5.0 (1.9-7.7) 0.003
Triglycerides (mmol/L) 1.2 (0.6-5.3) 0.9 (0.1-2.1) 0.018
Glucose (mmol/L) 5.4 (3.5-8.7) 5.2 (3.0-7.4) 0.166
Insulin (pmol/L) 256 (36-687) 135 (24-626) <0.001
Adiponectin (μg/mL) 7.8 (0.8-19.5) 8.0 (1.1-34.9) 0.001
hsCRP (nmol/L) 9.1 (0.1-225.5) 9.1 (0.0-193.6) 0.822
Results are expressed as median (range). 1 Body condition score assessed with
a 9-integer scale [19]. 2 Systolic blood pressure, measured indirectly by an
oscillometric technique. 3 Urine protein:creatinine ratio. For UPCR, due to lack
of availability of urine samples, was measured on 30/35 dogs. All results are
expressed as mean, median (range) & number above upper limit; the exception
is except for body condition score (BCS), where the mean values are not
reported as the data were categorical. hsCRP: high-sensitivity C-reactive protein.weight loss outcomes and plasma metabolic biomarker
concentrations were compared between dogs that either
did or did not fit the definition. Plasma adiponectin
concentration was less in dogs with metabolic syndrome
(P= 0.031), whilst plasma insulin concentration was
greater (P= 0.030; Table 4), and they were negatively cor-
related with one another (Kendall’s tau -0.29, P= 0.016).
However, none of the other parameters, including as-
sessment of total and regional body fat or weight loss
rate differed between groups (P > 0.1 for all).
Discussion
Human MS is now well recognized and predisposes to
cardiovascular diseases and type 2 diabetes mellitus [1].
In equine MS, obesity, regional adiposity, insulin resist-
ance, hypertriglyceridaemia and hyperleptinaemia are
part of the definition, and it is a risk factor for laminitis,
altered reproductive function, and seasonal alterations
in arterial blood pressure [6,9]. In the current study,
we classified pet dogs with naturally-occurring obesity
on the basis of presence of ORMD (using a modification
of criteria used for human metabolic syndrome). We
then examined the effect of weight loss on these meta-
bolic criteria, and sought to identify factors that were
potentially associated with the syndrome. The criteria
for ORMD were met in approximately 20% of obese
patients pre-weight loss. The presence of ORMD was
not associated with total fat mass, as measured by
DEXA, but was associated with increased and decreased
plasma insulin and adiponectin concentrations, respect-
ively. These findings suggest that defining obese dogs on
the basis of their metabolic status may have some merit,
although further work is now required to determine the
true significance of ORMD in terms of disease risk and
outcome. Weight loss was associated with decreased
body fat mass, BCS, SBP, circulating lipid concen-
trations, and plasma insulin concentration, whilst circu-
lating adiponectin increased. These findings are similar
Table 4 Comparison pre-weight loss parameters in obese dogs with and without metabolic syndrome
Criterion Metabolic syndrome No metabolic syndrome P
Age mo 98 (31 to 132) 66 (12 to 132) 0.335
Sex1 5 NM, 2 NF 1 M, 14 NM, 2 F, 11 NF 0.835
Breed2 Dachshund, Doberman, English Bull Terrier,
Irish Setter, Labrador, Lhasa Apso, Mixed Breed
Akita, Border Collie, Cairn Terrier, CKCS (3),
Cocker Spaniel, Corgi, Doberman, Golden Retriever,
Labrador (8), Miniature Schnauzer, Mixed Breed (2),
Pug (3), Samoyed, Schipperke, Yorkshire Terrier (2)
0.321
Start weight kg 42.8 (8.5 to 56.3) 28.6 (5.4 to 77.0) 0.479
Total BF3 % 47 (37 to 51) 44 (30 to 55) 0.424
Weight loss % 28 (16 to 44) 28 (9 to 38) 0.531
Weight loss rate %/wk 0.7 (0.2 to 1.4) 0.8 (0.3 to 1.4) 0.642
EI during weight loss4 62 (53 to 74) 60 (44 to 74) 0.672
Change in lean mass % -7 (-21 to -2) -7 (-20 to 10) 0.537
Adiponectin μg/mL 4.1 (2.4 to 8.1) 8.4 (0.8 to 19.5) 0.031
Insulin pmol/L 428 (125 to 686) 222 (36 to 524)
μIU/mL 62 (18 to 99) 32 (5 to 75) 0.030
hs-CRP nmoL/L 7.0 (0.1 to 56.6) 11.1 (4.0 to 214.8) 0.719
1 For sex, F: female, NF: neutered female, NM: neutered male. Upper limit: the upper reference range limit used for the definition of metabolic syndrome. 2 For
Breed, CKCS: Cavalier King Charles spaniel. 3 Total body fat measured by dual-energy X-ray absorptiometry. 4 Energy intake for weight loss is the median value for
the whole of weight loss, expressed as energy (in Kcal) per kg metabolic body weight (kg0.75)/day. All results are expressed as median (range).
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[11-13,28], and suggest that the study population was rep-
resentative. Nonetheless, the study was small and extend-
ing the work further studies would now be desirable.
We chose to base our ORMD definition on the guide-
lines of the International Diabetes Federation [22], al-
though other guidelines are available including those of
the World Health Organization [29], the European
Group for the Study of Insulin Resistance [30], the
National Cholesterol Education Program [31], and a
combined statement from the American Heart Associ-
ation and National Heart, Lung, and Blood Institute
[32]. The main reason for this was that the criteria used
could readily be adapted to produce a practical method
in dogs. For each criterion used, and in a similar manner
to humans, either the upper limit of the respective
laboratory reference ranges (e.g. cholesterol, triglyceride,
and glucose), or internationally accepted criteria, above
which the parameter is borderline (e.g. SBP) [23] was
chosen as the cut-off. Whilst many of the criteria were
identical to those used in the human system, others were
substituted for similar parameters thought to be more
relevant for dogs. The main advantages of such an ap-
proach were that all chosen parameters are already in
2widespread clinical use and techniques for measure-
ment are better validated, thereby making the whole
system more accessible for practicing veterinarians. For
example, we replaced waist circumference (a human
measure of central obesity), with BCS, since the signifi-
cance of central obesity has not been studied in dogs.
Given differences in canine anatomy, the human mea-
sures of central adiposity are not likely to be appropriatefor dogs, and developing a clinical measure of abdominal
obesity in dogs (e.g. waist circumference) would be chal-
lenging given the wide variability in size and shape
amongst breeds. In contrast, differences in BCS are asso-
ciated with both disease risk and decreased longevity
[14,15]. Nonetheless, it may be necessary to modify these
criteria in the future, if a practical method of measuring
central obesity can be validated.
In a similar manner, total plasma cholesterol concen-
tration was used in place of HDL-cholesterol. The main
reason for this modification was the fact that lipid pro-
files differ between dogs and humans, with humans
demonstrating an ‘LDL pattern’, whilst HDL is the dom-
inant cholesterol type in dogs [33]. Further, alterations
in lipoprotein profiles differ in human and canine obes-
ity: obese humans display increased LDL-cholesterol and
decreased HDL-cholesterol [1], whereas the circulating
concentrations of both LDL and HDL-cholesterol are
increased in obese dogs [11,34]. Thus, the use of total
cholesterol, rather than cholesterol fractions, is more
logical for the latter species.
Based upon definitions of 4 (i.e. SBP, cholesterol, tri-
glyceride and glucose) parameters in addition to BCS,
approximately 20% of the obese dogs of the study
were classified with ORMD, respectively. This suggests
that the prevalence of MS in obese dogs is some-
what less than for humans where prevalence is typically
22-28% and 50-60% in overweight and obese patients,
respectively [35]. The reasons for such a difference
are not known, and further elucidation of the underly-
ing mechanisms of ORMD is recommended for com-
parative purposes.
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chose to assess a variety of other parameters including
fasting insulin concentration, plasma adiponectin con-
centration, CRP and adiposity, as determined by DEXA.
When the obese dogs of the present study were subdi-
vided on presence or absence of ORMD prior to weight
loss, only plasma adiponectin and insulin concentrations
differed. Adiponectin was approximately twofold less,
and insulin approximately twofold greater, in the ORMD
group, and both were negatively correlated with one an-
other. This finding is similar to that described in the
human literature on MS [36]. In man, one of the major
obesity and MS outcomes is insulin resistance and type
2 diabetes mellitus [1], and the risk of this condition is
increased fivefold when MS is present [2]. The exact
pathogenetic link between obesity and insulin resistance
has not yet been fully elucidated [37]. However, adipo-
nectin is known to have an insulin-sensitizing effect,
acting through the AMP-activated protein kinase [38],
so that the association with MS may (at least in part) be
explained by the decreased adiponectin concentration
that accompanies obesity. Adiponectin may also have
anti-inflammatory effects, such that decreased adiponec-
tin concentrations are associated with the increased risk
of inflammation [39]. Thus, hypoadiponectinaemia
observed in human MS may be responsible for develop-
ment of secondary diseases due to increased susceptibil-
ity to inflammation and insulin resistance. Interestingly,
no difference was noted in hsCRP, either when compari-
sons were made before and after weight loss, or when
obese dogs were categorized as either having or nor
having concurrent ORMD. This may suggest that asso-
ciations amongst adiponectin, MS and obesity are inde-
pendent of the function of this particular acute phase
protein. Further, these findings are different from some
previous studies examining CRP concentrations in obese
dogs, where increased [12,40] or decreased [13] concen-
trations have been seen. The reasons for such differences
are not entirely clear, but may have resulted from differ-
ences in the test populations and assay used. Most not-
ably, our work utilized a high-sensitivity assay recently
validated for dogs [26], and such assays are thought to
be more reliable in humans [41]. The findings regarding
adiponectin concentrations in the current study are dif-
ferent from some [12,42] but not other [43] studies.
Again, the reasons for this are not clear but similar
explanations would be feasible, namely that this related
to population differences or assay type. In the present
study, we used a high sensitivity human adiponectin
ELISA assay previously validated for use in dogs [34]. In
this assay, human calibrators were substituted for
species-specific standards, in order to achieve similar
affinity of antiserum against standards; this ensures that
better differentiation between samples with greater andlesser adiponectin concentrations [34]. Nonetheless, high
and low molecular weight adiponectin species were not
measured in the current study, and these may differ in
importance is development of obesity-associated conse-
quences [44]. Thus, the true significance of these find-
ings requires further study.
The presence of increased plasma insulin concentra-
tion, and decreased plasma adiponectin concentration
implies physiological consequences to ORMD. However,
in order to determine its true significance, further inves-
tigations would be needed examining other biomarkers
and also clinical consequences. For example human MS
is associated with dysregulated fatty acid metabolism
[45], cardiac and vascular functional derangements [46],
and hepatic manifestations such as non-alcoholic fatty
liver disease [47]. Therefore, future studies could assess
alterations in a variety of biomarkers in a prospective
population of dogs. Epidemiological studies could also be
considered, as a means of determining potential disease
associations and, ultimately, risk of death in ORMD.
Another interesting observation from the current
study was the fact that no differences in fat mass were
identified between dogs classified with or without MS.
This implies that canine obesity does not inevitably lead
to metabolic dysfunction, and is similar to findings in
man, where some obese individuals are determined to be
metabolically healthy [48]. These patients are not insulin
resistant, are normotensive, and have normal plasma
concentrations of triglyceride, glucose, high-sensitivity
C-reactive protein (hsCRP), and high-density lipoprotein
(HDL) cholesterol. The reasons why some dogs may be
protected from developing metabolic derangements of
obesity are not known and require further study. Pos-
sible explanations, not examined in the current study
include the age of onset obesity, time taken to become
obese, duration of obesity prior to weight loss, and the
type of diet fed during the obese stage. As a result, fur-
ther work is required to determine the mechanisms
involved in the development of ORMD.
As is often the case, this study has limitations that
should be considered. The main study limitation was
that client-owner out bred dogs were used, which
undoubtedly added to study variability. For instance,
environment, diet, exercise and husbandry were variable.
Most notable is the issue of diet, since the amount of
food eaten, and type of diet could have influenced the
pre-weight-loss metabolic parameters, particularly chol-
esterol and triglycerides. Unfortunately, the information
obtained from the owner regarding diet fed before enrol-
ment was vague and incomplete. A range of foods was
fed, including commercial pet food, treats, and human
food. Further, owners frequently fed many different
diets, rarely measured the amount fed out accurately,
and did not record the extra food fed. As a result, it was
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weight-loss feeding that could be used in this study. Fur-
ther, information was unclear as to the exact duration of
obesity in many cases and, again, this may have influ-
enced the results obtained. Moreover, ethical limitations
meant that we were unable to perform more invasive
but gold standard assessments of insulin sensitivity such
as hyperinsulinaemic, euglycaemic clamps or minimal
model analysis to determine insulin sensitivity [49,50].
That said, the obesity had developed naturally and been
longstanding (e.g. >12 months) in most cases, which is
arguably more representative of the at-risk population of
interest. Nonetheless, it would be sensible to consider
further studies as a means of elucidating the underlying
mechanisms of ORMD more precisely.
Conclusions
In conclusion, this study has described that up to a third
of obese dogs do suffer from ORMD, which is character-
ized by hypoadiponectinaemia and hyperinsulinaemia.
This study can form the basis of further investigations to
determine pathogenetic mechanisms and the health sig-
nificance for dogs, in terms of disease associations and
outcomes of weight loss.
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